Timothy Wright

Timothy R.
Wright founded Ohio State University Comprehensive Cancer Center in 2011, where he worked as Director and Signal Hill Advisors LLC in 2011, where he is working as Partner from 2011.
Mr. Wright also founded Mortimer Capital.
Mr. Wright also currently works at Isosceles Pharmaceuticals, Inc., as Executive Chairman from 2019, Ohio State University Comprehensive Cancer Center, as Chairman, Agenus, Inc., as Lead Independent Director from 2009, Protagenic Therapeutics, Inc., as Independent Director from 2025, Washington University School of Medicine, as Director, and College of Veterinary Medicine (North Carolina), as Director.
Mr. Wright also formerly worked at AAIPharma, Inc., as President & Interim Chief Executive Officer from 2004 to 2006, MiMedx Group, Inc., as Chief Executive Officer & Director from 2019 to 2022, Aster Insights, as President & Chief Executive Officer from 2017 to 2018, Curaxis Pharmaceutical Corp., as Chairman & Chief Executive Officer in 2012, ParagonRx International LLC, as Chairman from 2006 to 2007, Protagenic Therapeutics, Inc., as Lead Independent Director from 2022 to 2025, CeNeS Pharmaceuticals Plc, as Director from 2007 to 2010, Ohio State Innovation Foundation, as Director, Cardinal Health, Inc., as Senior Vice President-Healthcare Product Services from 1999 to 2001, DuPont Merck Pharmaceutical Co., as President, SVP-Strategy & Business Development from 1984 to 1999, Xanodyne Pharmaceuticals, Inc., as Chief Operating Officer from 2005 to 2006, Covidien New Zealand Ltd., as President-Pharmaceuticals & Senior Vice President in 2007, Covidien Unlimited Co., as President-Pharmaceuticals & Senior Vice President from 2007 to 2010, Elan Biopharmaceuticals, Inc., as VP-International Marketing & General Manager from 2001 to 2004, and Teva Pharmaceutical Industries Ltd., as EVP-Mergers & Acquisitions, Strategy, Innovation from 2015 to 2017.
Mr. Wright received his undergraduate degree in 1981 from The Ohio State University.